A clinical study showed a reduction of alternating constipation and diarrhea for the participants taking DE111 (1 billion CFU) when compared to participants taking the placebo. The proportion of normal stools (types 3 and 4) increased from 54% to 64% in the DE111 group, while the proportion of normal stools decreased from 56% to 48% in the placebo group. In male participants specifically, the proportion of normal stools increased from 56% to 80%. In addition, a significant difference between the DE111 and placebo groups was observed in regards to normal and non-normal stool proportions in the 30+ age group.
Deerland is proud to announce that the FDA has issued a GRAS (Generally Recognized As Safe) No Objection Letter for…More
Parents see digestive supplements as allies in keeping their kids healthy physically and mentally in these uncertain times; a way…More
Deerland Probiotics & Enzymes is pleased to announce that it has earned Non-GMO Project verification for its branded probiotic, DE111, as…More